Deal Type: Asset Transaction
Deal Country: United States of America
Deal Status: Completed
Deal Value: 0.0000 USD
Deal in Brief
Xellia Pharmaceuticals ApS, a pharmaceutical company, has acquired manufacturing facilities from Hikma Pharmaceuticals PLC, a pharmaceutical company.
Under the terms of the agreement, Xellia Pharma acquired substantial parts of the site including several new manufacturing units for sterile injectables which are not currently operational. Hikma pharma will retain the remaining facilities including the quality and development center (QDC) which has been operated by its subsidiary, West-Ward Injectables, Inc. since it acquired the site in 2014.
The manufacturing facilities are located in Bedford, Ohio, US. The manufacturing facilities are previously owned by Ben Venue Laboratories, Inc. Earlier on September 17, 2014, Hikma Pharma acquired the Ben Venue assets from Boehringer Ingelheim, following its agreement to purchase the assets of Bedford Laboratories.
Following the transaction, Xellia Pharma plans to begin commercial production at the site within 24 months. The facility will operate alongside the company’s existing sterile injectables production plant in Raleigh, North Carolina, US.
This transaction enables Xellia Pharma to significantly strengthen its manufacturing capacity, alleviating supply shortage for vital anti-infectives in US.
Index - Sterilization and Disinfectant Equipment
Index - United States of America
(c) 2015 Progressive Media Group Metadata. All rights reserved. Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Progressive Media Group Metadata shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon., source PDM Deals